Latest Health News

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.

Live Verdure Ltd has secured a controlling stake in AI innovator Decidr.ai and reported robust e-commerce growth for its Edible Beauty brand, underscoring its strategic pivot towards AI-driven expansion.

Little Green Pharma reports a robust 75% revenue increase to $9.5 million for December quarter, driven by strong European market growth and strategic product launches.

Adherium reports strong patient adoption and new US partnerships, positioning for significant expansion in 2025 with a target of 9,000 active users and entry into the Pharmacy Benefit Management sector.

Norwood Systems has secured a fifth variation to its cash drawdown facility, increasing the principal to $720,114 and extending repayment to mid-February 2025. The move underscores ongoing financial support from a key director amid evolving capital needs.

Ramsay Health Care announces key leadership departures and a strategic realignment aimed at strengthening its core Australian hospital business and accelerating transformation under CEO Natalie Davis.

ImpediMed Limited has reported record quarterly revenue and cash receipts for Q2 FY25, alongside significant growth in reimbursement coverage and a robust sales pipeline, signaling strong momentum in its digital health platform business.

Optiscan Imaging Ltd has secured a $1.775 million R&D tax refund for FY24, more than doubling last year’s amount thanks to expanded claims on overseas research. The boost will fund ongoing development of its cutting-edge confocal laser endomicroscopy technology.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.

ResMed Inc. posted a robust second quarter for fiscal year 2025, with revenue climbing 10% to $1.3 billion and operating profit soaring 52%, driven by strong demand for sleep and breathing health products and operational efficiencies.

Almonty Industries has locked in final commitments for an AUD 18.45 million equity placement from existing shareholders, aiming to strengthen its financial position and cover offer costs. The placement includes warrants and options, with closing pending regulatory approval.

TrivarX has solidified its regulatory strategy for the pivotal MEB-001 trial with the FDA and unveiled a new algorithm that expands its mental health screening reach beyond sleep clinics.